MedTrace Logo

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

NCT01782989 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2022-11-04

No results posted yet for this study

Summary

This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).

Conditions

Interventions

DRUG

ORACEA®

ORACEA® (40mg doxycycline) capsule daily for 24 months

DRUG

Placebo

Placebo capsule daily for 24 months

Sponsors & Collaborators

  • MEDARVA Foundation

    collaborator UNKNOWN

  • Paul Yates, MD, PhD

    lead OTHER

Principal Investigators

  • Paul A Yates, MD, PhD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782989 on ClinicalTrials.gov